Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Secondary
1.6.1.1 Paid sources
1.6.1.2 Public sources
1.6.2 Primary
Chapter 2 Executive Summary
2.1 Sleep medications industry 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 Drug class trends
2.1.5 Sleep disorder type trends
Chapter 3 Sleep Medications Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of sleep disorders
3.2.1.2 Stressful lifestyles of people
3.2.1.3 Advancements in drug development
3.2.1.4 Growth in aging population across the globe
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side effects associated with sleeping medications
3.2.2.2 Availability of alternative Therapies
3.2.2.3 Limited insurance coverage for sleep medications
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By drug class
3.3.3 By sleep disorder type
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter’s analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022
Chapter 5 Sleep Medications Market, By Type, 2018 - 2032 (USD Million)
5.1 Key trends, by type
5.2 Prescription-based drugs
5.3 OTC drugs
Chapter 6 Sleep Medications Market, By Drug Class, 2018 – 2032 (USD Million)
6.1 Key trends, by drug class
6.2 Benzodiazepines
6.3 Antidepressants
6.4 Antihistamines
6.5 Sedating antipsychotics
6.6 Other drug classes
Chapter 7 Sleep Medications Market, By Sleep Disorder Type, 2018 – 2032 (USD Million)
7.1 Key trends, by sleep disorder
7.2 Insomnia
7.3 Sleep apnea
7.4 Restless legs syndrome
7.5 Narcolepsy
7.6 Sleep walking
7.7 Other sleep disorders
Chapter 8 Sleep Medications Market, By Region, 2018 - 2032 (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Pfizer Inc.
9.2 Sanofi SA
9.3 Eisai Co., Ltd.
9.4 Sunovion Pharmaceuticals Inc.
9.5 Merck and Co Inc.
9.6 Takeda Pharmaceutical Company Limited
9.7 Johnson & Johnson
9.8 Novartis AG
9.9 Vanda Pharmaceuticals
9.10 Teva Pharmaceuticals
